AI Virtanen Institute, Department of Biotechnology and Molecular Medicine, University of Eastern Finland, PO Box 1627, FI-70211 Kuopio, Finland.
J Invertebr Pathol. 2011 Jul;107 Suppl:S71-9. doi: 10.1016/j.jip.2011.05.007.
Serum inactivation of baculovirus vectors is a significant barrier to the development of these highly efficient vectors for therapeutic gene delivery. In this review we will describe the efforts taken to avoid complement attack by passive or active measures. Evidently good targets for baculovirus-mediated gene delivery include immunoprivileged tissues, such as eye, brain and testis. Similarly baculovirus vectors have also proven their efficacy in an ex vivo setting for tissue engineering. Active measures to inhibit complement include the use of pharmacological inhibitors of complement as well as surface engineering of the baculoviral vectors through the use of synthetic polymers, pseudotyping or display of complement inhibitors. Lessons learned from these studies will significantly increase the possibility of using baculovirus vectors for therapeutic applications.
杆状病毒载体的血清失活是开发这些高效治疗性基因传递载体的重大障碍。在这篇综述中，我们将描述通过被动或主动措施避免补体攻击所做的努力。显然，杆状病毒介导的基因传递的良好靶标包括免疫特惠组织，如眼、脑和睾丸。同样，杆状病毒载体在组织工程的体外环境中也已证明其有效性。抑制补体的主动措施包括使用补体药理学抑制剂以及通过使用合成聚合物、假型化或补体抑制剂的展示来对杆状病毒载体进行表面工程改造。从这些研究中吸取的经验教训将极大地增加杆状病毒载体用于治疗性应用的可能性。
